Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B

Larabi, M; Yardley, V; Loiseau, PM; Appel, M; Legrand, P; Gulik, A; Bories, C; Croft, SL; Barratt, G; (2003) Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B. Antimicrobial agents and chemotherapy, 47 (12). pp. 3774-3779. ISSN 0066-4804 DOI:

Full text not available from this repository.


The aim of the present study was to evaluate the toxicity and the activity of a new lipid complex formulation of amphotericin B (AMB) (LC-AMB; dimyristoyl phosphatidylcholine, dimyristoyl phosphatidylglycerol, and AMB) that can be produced by a simple process. Like other lipid formulations, this new complex reduced both the hemolytic activity of AMB (the concentration causing 50% hemolysis of human erythrocytes, >100 micro g/ml) and its toxicity toward murine peritoneal macrophages (50% inhibitory concentration, >100 micro g/ml at 24 h). The in vivo toxicity of the new formulation (50% lethal dose, >200 mg/kg of body weight for CD1 mice) was similar to those of other commercial lipid formulations of AMB. The complex was the most effective formulation against the DD8 strain of Leishmania donovani. It was unable to reverse the resistance of an AMB-resistant L. donovani strain. In vivo LC-AMB was less efficient than AmBisome against L. donovani.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection
Research Centre: Leishmaniasis Group
Malaria Centre
Neglected Tropical Diseases Network
PubMed ID: 14638481
Web of Science ID: 186921500018


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item